Sequoia Genetics published the LUMUS results in systemic lupus erythematosus (SLE) showing that partial loss-of-function variants, including P1104A (rs34536443), are associated with lower disease risk and reduced TYK2-dependent signalling.
Published
Signal category
Research & Knowledge
Quote
“The recent LUMUS results in systemic lupus erythematosus (SLE) provide an informative example of how human genetics may contribute to clinical development beyond target selection.”
— Dipender Gill|Sequoia Genetics team
Company
Sequoia Genetics
Experts in leveraging genetic data for generating translational insights.
- Industry
- Research Services
- Location
- London, GB
- Company size
- 18 employees
Sequoia Genetics is dedicated to transforming genetic data into actionable insights. We work with life sciences investors, pharmaceutical and biotech companies to translate genetic evidence into drug discovery and drug development decisions. Our team is made up of biologists, clinicians, epidemiologists, statisticians, data scientists, bioinformaticians and industry experts that have collectively published hundreds of research papers in the field and are vastly experienced in translating genetic insights to guide clinical development decisions.
Founded 2024